FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569445386> ?p ?o ?g. }

• W1569445386 endingPage "20" @default.
• W1569445386 startingPage "11" @default.
• W1569445386 abstract "Earlier studies have shown that infants with untreated congenital toxoplasmosis and generalized or neurologic abnormalities at presentation almost uniformly develop mental retardation, seizures, and spasticity. Children with untreated subclinical disease at birth have developed seizures, significant cognitive and motor deficits, and diminution in cognitive function over time.To determine neurologic, cognitive, and motor outcomes for children with congenital toxoplasmosis who were treated for approximately 1 year with pyrimethamine and sulfadiazine.Systematic, prospective, and longitudinal neurologic, cognitive, and motor evaluations were performed for 36 individuals with congenital toxoplasmosis. These infants were born between December 1981 and January 1991 and were treated with pyrimethamine and sulfadiazine for approximately 1 year beginning in the first months of life. Compliance with medications was documented. These individuals were evaluated in a standardized manner in a single center in the first months of life and at approximately 1, 3.5, 5, 7.5, and 10 years of age. Their cognitive function was compared with the cognitive function of a nearest-age, same-sex sibling when such siblings older than 3.5 years were available for study.Signs of active central nervous system infection (eg, cerebrospinal fluid [CSF] pleiocytosis, hypoglycorrhachia, elevated CSF protein, and, in some instances, seizures and motor abnormalities) resolved during therapy. Six of the 36 children had perinatal seizures. Four had their anticonvulsant therapy discontinued successfully within the first months of life, and two additional children developed new seizures at 3 and 5 years of age. Tone and motor abnormalities resolved by 1 year of age in 12 of 20 infants who exhibited abnormalities of tone and motor function at their initial neonatal evaluation. By February 1992, 29 of the 36 children had been evaluated when they were 1 year old, and 23 (79%) had a mean +/- standard deviation Mental Developmental Index (MDI) of 102 +/- 22 (range, 59 to 140). Six (21%) had a measure of their cognitive function that was less than 50. Results of sequential IQ tests, performed at 1.5 year intervals or greater, did not differ significantly over time (P > .05). Seven children with MDIs greater than 50 were compared with sibling controls; they had scores of 87 +/- 11 (range, 68 to 97) and their siblings had scores of 112 +/- 15 (range, 85 to 132) (P = .008). Seventeen of 18 children without hydrocephalus and six of eight children with obstructive hydrocephalus responsive to shunting had normal or near-normal neurologic and developmental outcomes. Children with hydrocephalus ex vacuo present at birth, with high CSF protein, and with lack of response to shunting have done less well.Neurologic and developmental outcomes were significantly better for most of these treated children than outcomes reported for untreated children or those treated for only 1 month (P < .001). Although the level of cognitive function for treated children was less than for their uninfected siblings (P < .008), there was no significant deterioration in neurologic and cognitive function of the treated children tested sequentially. These favorable treatment outcomes justify systematic identification and treatment of pregnant women with acute gestational Toxoplasma infection and young infants with congenital toxoplasmosis." @default.
• W1569445386 created "2016-06-24" @default.
• W1569445386 creator A5004817094 @default.
• W1569445386 creator A5006764293 @default.
• W1569445386 creator A5011202703 @default.
• W1569445386 creator A5012534523 @default.
• W1569445386 creator A5015165280 @default.
• W1569445386 creator A5025678389 @default.
• W1569445386 creator A5035216278 @default.
• W1569445386 creator A5049114543 @default.
• W1569445386 creator A5053981478 @default.
• W1569445386 creator A5056510796 @default.
• W1569445386 creator A5069253432 @default.
• W1569445386 creator A5076400884 @default.
• W1569445386 creator A5078833950 @default.
• W1569445386 creator A5080789143 @default.
• W1569445386 creator A5090595212 @default.
• W1569445386 creator A5091552402 @default.
• W1569445386 date "1995-01-01" @default.
• W1569445386 modified "2023-09-23" @default.
• W1569445386 title "Neurologic and developmental outcome in treated congenital toxoplasmosis." @default.
• W1569445386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7770286" @default.
• W1569445386 hasPublicationYear "1995" @default.
• W1569445386 type Work @default.
• W1569445386 sameAs 1569445386 @default.
• W1569445386 citedByCount "61" @default.
• W1569445386 countsByYear W15694453862013 @default.
• W1569445386 countsByYear W15694453862014 @default.
• W1569445386 countsByYear W15694453862015 @default.
• W1569445386 countsByYear W15694453862016 @default.
• W1569445386 countsByYear W15694453862017 @default.
• W1569445386 countsByYear W15694453862018 @default.
• W1569445386 countsByYear W15694453862019 @default.
• W1569445386 countsByYear W15694453862022 @default.
• W1569445386 crossrefType "journal-article" @default.
• W1569445386 hasAuthorship W1569445386A5004817094 @default.
• W1569445386 hasAuthorship W1569445386A5006764293 @default.
• W1569445386 hasAuthorship W1569445386A5011202703 @default.
• W1569445386 hasAuthorship W1569445386A5012534523 @default.
• W1569445386 hasAuthorship W1569445386A5015165280 @default.
• W1569445386 hasAuthorship W1569445386A5025678389 @default.
• W1569445386 hasAuthorship W1569445386A5035216278 @default.
• W1569445386 hasAuthorship W1569445386A5049114543 @default.
• W1569445386 hasAuthorship W1569445386A5053981478 @default.
• W1569445386 hasAuthorship W1569445386A5056510796 @default.
• W1569445386 hasAuthorship W1569445386A5069253432 @default.
• W1569445386 hasAuthorship W1569445386A5076400884 @default.
• W1569445386 hasAuthorship W1569445386A5078833950 @default.
• W1569445386 hasAuthorship W1569445386A5080789143 @default.
• W1569445386 hasAuthorship W1569445386A5090595212 @default.
• W1569445386 hasAuthorship W1569445386A5091552402 @default.
• W1569445386 hasConcept C113280763 @default.
• W1569445386 hasConcept C118552586 @default.
• W1569445386 hasConcept C126322002 @default.
• W1569445386 hasConcept C187212893 @default.
• W1569445386 hasConcept C203014093 @default.
• W1569445386 hasConcept C2778062946 @default.
• W1569445386 hasConcept C2778186239 @default.
• W1569445386 hasConcept C71924100 @default.
• W1569445386 hasConceptScore W1569445386C113280763 @default.
• W1569445386 hasConceptScore W1569445386C118552586 @default.
• W1569445386 hasConceptScore W1569445386C126322002 @default.
• W1569445386 hasConceptScore W1569445386C187212893 @default.
• W1569445386 hasConceptScore W1569445386C203014093 @default.
• W1569445386 hasConceptScore W1569445386C2778062946 @default.
• W1569445386 hasConceptScore W1569445386C2778186239 @default.
• W1569445386 hasConceptScore W1569445386C71924100 @default.
• W1569445386 hasIssue "1" @default.
• W1569445386 hasLocation W15694453861 @default.
• W1569445386 hasOpenAccess W1569445386 @default.
• W1569445386 hasPrimaryLocation W15694453861 @default.
• W1569445386 hasRelatedWork W1989881279 @default.
• W1569445386 hasRelatedWork W2052220912 @default.
• W1569445386 hasRelatedWork W2099022924 @default.
• W1569445386 hasRelatedWork W2109718093 @default.
• W1569445386 hasRelatedWork W2396996042 @default.
• W1569445386 hasRelatedWork W2744822251 @default.
• W1569445386 hasRelatedWork W2905372780 @default.
• W1569445386 hasRelatedWork W3117735050 @default.
• W1569445386 hasRelatedWork W52927571 @default.
• W1569445386 hasRelatedWork W2379484667 @default.
• W1569445386 hasVolume "95" @default.
• W1569445386 isParatext "false" @default.
• W1569445386 isRetracted "false" @default.
• W1569445386 magId "1569445386" @default.
• W1569445386 workType "article" @default.